These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30595104)

  • 1. Efficacy and safety of nivolumab in patients with non-small cell lung cancer: a retrospective study in clinical practice.
    Montana M; Garcia ME; Ausias N; Jeanpierre M; Meiffren M; Giorgi R; Vanelle P; Barlesi F
    J Chemother; 2019 Apr; 31(2):90-94. PubMed ID: 30595104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
    Morita R; Okishio K; Shimizu J; Saito H; Sakai H; Kim YH; Hataji O; Yomota M; Nishio M; Aoe K; Kanai O; Kumagai T; Kibata K; Tsukamoto H; Oizumi S; Fujimoto D; Tanaka H; Mizuno K; Masuda T; Kozuki T; Haku T; Suzuki H; Okamoto I; Hoshiyama H; Ueda J; Ohe Y
    Lung Cancer; 2020 Feb; 140():8-18. PubMed ID: 31838169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicentre observational study of the effectiveness, safety and economic impact of nivolumab on non-small-cell lung cancer in real clinical practice.
    Merino Almazán M; Duarte Pérez JM; Marín Pozo JF; Ortega Granados AL; Muros De Fuentes B; Quesada Sanz P; Gago Sánchez AI; Rodríguez Gómez P; Jurado García JM; Artime Rodríguez-Hermida F; Martínez Bautista MJ; Rueda Ramos A; Mora Rodríguez B; Martínez Díaz MC; Nieto Guindo P; Garrido Siles M; Villatoro Roldán R; Roldán Morales JC; Artacho Criado SM; Baños Roldán Ú; Inoriza Rueda Á; Garrido Martínez MT
    Int J Clin Pharm; 2019 Feb; 41(1):272-279. PubMed ID: 30578473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data.
    Dudnik E; Moskovitz M; Daher S; Shamai S; Hanovich E; Grubstein A; Shochat T; Wollner M; Bar J; Merimsky O; Zer A; Goldstein DA; Hammerman A; Cyjon A; Shechtman Y; Abu-Amna M; Flex D; Roisman LC; Peled N;
    Lung Cancer; 2018 Dec; 126():217-223. PubMed ID: 29254746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Nivolumab in Previously Treated Patients With Non-Small-cell Lung Cancer: Real World Experience in Argentina.
    Martin C; Lupinacci L; Perazzo F; Bas C; Carranza O; Puparelli C; Kowalyszyn R; Magri I; Varela M; Richardet E; Vera K; Foglia S; Jerez I; Aman E; Martinengo G; Batagelj E; Dri A; Pilnik N; Roa GM; Mando P; Tsou F; Recondo G; Cayol F; Flores M; Sena S; Bagnes C; Waisberg FD; Minatta JN; Rizzo M
    Clin Lung Cancer; 2020 Sep; 21(5):e380-e387. PubMed ID: 32213298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
    Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
    Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
    Gauvain C; Vauléon E; Chouaid C; Le Rhun E; Jabot L; Scherpereel A; Vinas F; Cortot AB; Monnet I
    Lung Cancer; 2018 Feb; 116():62-66. PubMed ID: 29413052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world Efficacy and Safety of Nivolumab for Advanced Non-Small-cell Lung Cancer: A Retrospective Multicenter Analysis.
    Kobayashi K; Nakachi I; Naoki K; Satomi R; Nakamura M; Inoue T; Tateno H; Sakamaki F; Sayama K; Terashima T; Koh H; Abe T; Nishino M; Arai D; Yasuda H; Kawada I; Soejima K; Betsuyaku T;
    Clin Lung Cancer; 2018 May; 19(3):e349-e358. PubMed ID: 29398578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.
    Grossi F; Genova C; Crinò L; Delmonte A; Turci D; Signorelli D; Passaro A; Soto Parra H; Catino A; Landi L; Gelsomino F; Tiseo M; Puppo G; Roila F; Ricciardi S; Tonini G; Cognetti F; Toschi L; Tassinari D; Scoppola A; Giannarelli D; Cortesi E
    Eur J Cancer; 2019 Dec; 123():72-80. PubMed ID: 31671314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
    Garassino MC; Crinò L; Catino A; Ardizzoni A; Cortesi E; Cappuzzo F; Bordi P; Calabrò L; Barbieri F; Santo A; Altavilla G; Ambrosio F; Mini E; Vasile E; Morgillo F; Scoppola A; Bengala C; Follador A; Tedde N; Giannarelli D; Lo Russo G; Vitiello F
    Tumour Biol; 2018 Nov; 40(11):1010428318815047. PubMed ID: 30486741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer.
    Takeda T; Takeuchi M; Saitoh M; Takeda S
    Thorac Cancer; 2018 Oct; 9(10):1291-1299. PubMed ID: 30126063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
    Tournoy KG; Thomeer M; Germonpré P; Derijcke S; De Pauw R; Galdermans D; Govaert K; Govaerts E; Schildermans R; Declercq I; De Brucker N; Pat K; Van Herreweghe R; Van Zandweghe L; Vanmaele L; Van Damme V; Marien H; De Craene S; Fabry I; Alexander P; Vercauter P; Demedts I
    Lung Cancer; 2018 Jan; 115():49-55. PubMed ID: 29290261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.
    Ricciuti B; Genova C; Bassanelli M; De Giglio A; Brambilla M; Metro G; Baglivo S; Dal Bello MG; Ceribelli A; Grossi F; Chiari R
    Clin Lung Cancer; 2019 May; 20(3):178-185.e2. PubMed ID: 30910574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
    Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
    Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in previously treated Non Small Cell Lung Cancer (NSCLC).
    Figueiredo A; Almeida MA; Almodovar MT; Alves P; Araújo A; Araújo D; Barata F; Barradas L; Barroso A; Brito U; Camacho E; Canário D; Cardoso T; Chaves A; Costa L; Cunha J; Duarte J; Estevinho F; Felizardo M; Fernandes JP; Ferreira L; Ferreira L; Fidalgo P; Freitas C; Garrido P; Gil N; Hasmucrai D; Jesus E; Lopes JA; de Macedo JE; Meleiro A; Neveda R; Nogueira F; Pantorotto M; Parente B; Pego A; Rocha M; Roque J; Santos C; Saraiva J; Silva E; Silva S; Simões S; Soares M; Teixeira E; Timóteo T; Hespanhol V
    Pulmonology; 2020; 26(1):10-17. PubMed ID: 31630986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
    Giaj Levra M; Cotté FE; Corre R; Calvet C; Gaudin AF; Penrod JR; Grumberg V; Jouaneton B; Jolivel R; Assié JB; Chouaïd C
    Lung Cancer; 2020 Feb; 140():99-106. PubMed ID: 31911324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
    Grossi F; Crinò L; Logroscino A; Canova S; Delmonte A; Melotti B; Proto C; Gelibter A; Cappuzzo F; Turci D; Gamucci T; Antonelli P; Marchetti P; Santoro A; Giusti S; Di Costanzo F; Giustini L; Del Conte A; Livi L; Giannarelli D; de Marinis F
    Eur J Cancer; 2018 Sep; 100():126-134. PubMed ID: 30014881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
    Kim SH; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3025-3036. PubMed ID: 32583235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
    Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
    Lung Cancer; 2018 May; 119():14-20. PubMed ID: 29656747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.